- Home
- AARD vs FFNW Comparison
AARD vs FFNW Comparison
Compare AARD & FFNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- FFNW
- Stock Information
- Founded
- AARD 2017
- FFNW 1923
- Country
- AARD United States
- FFNW United States
- Employees
- AARD N/A
- FFNW N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- FFNW Banks
- Sector
- AARD Health Care
- FFNW Finance
- Exchange
- AARD Nasdaq
- FFNW Nasdaq
- Market Cap
- AARD 216.6M
- FFNW 208.6M
- IPO Year
- AARD 2025
- FFNW N/A
- Fundamental
- Price
- AARD $7.74
- FFNW $22.67
- Analyst Decision
- AARD Strong Buy
- FFNW Hold
- Analyst Count
- AARD 4
- FFNW 2
- Target Price
- AARD $31.50
- FFNW $22.75
- AVG Volume (30 Days)
- AARD 113.5K
- FFNW 61.2K
- Earning Date
- AARD 01-01-0001
- FFNW 04-29-2025
- Dividend Yield
- AARD N/A
- FFNW 0.57%
- EPS Growth
- AARD N/A
- FFNW N/A
- EPS
- AARD N/A
- FFNW 0.12
- Revenue
- AARD N/A
- FFNW $37,609,000.00
- Revenue This Year
- AARD N/A
- FFNW N/A
- Revenue Next Year
- AARD N/A
- FFNW $0.82
- P/E Ratio
- AARD N/A
- FFNW $194.23
- Revenue Growth
- AARD N/A
- FFNW N/A
- 52 Week Low
- AARD $7.74
- FFNW $18.03
- 52 Week High
- AARD $19.58
- FFNW $23.50
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- FFNW 65.74
- Support Level
- AARD N/A
- FFNW $22.60
- Resistance Level
- AARD N/A
- FFNW $22.76
- Average True Range (ATR)
- AARD 0.00
- FFNW 0.21
- MACD
- AARD 0.00
- FFNW 0.11
- Stochastic Oscillator
- AARD 0.00
- FFNW 96.98
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.